Potent body weight loss, and therapeutic efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP tri-agonist (HM15211) - Media Centre | EASD
Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions - Annie Hasib, 2020
Comparison of in vivo efficacy of next-generation triagonists to... | Download Scientific Diagram
Innovative Behandlungsmethoden - Duale und Triple-Agonisten – die Zukunft der Typ-2-Diabetestherapie?
Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis | Journal of Medicinal Chemistry
Pipeline | R&D
Clinical Focus on GLP-1 Agonists in Type 2 Diabetes Mellitus
Frontiers | GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist - ScienceDirect
Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations | Journal of Medicinal Chemistry
Ly3437943 (LY), a novel triple GIP/GLP-1/glucagon receptor agonist, provides glucose lowering and weight loss in patients with type 2 diabetes after 12 weeks of treatment | Medfyle
Nutrients | Free Full-Text | Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists
Triple combination therapy may be optimal for CV protection in type 2 diabetes
Alzheimer's: 'Triple-action' diabetes drug shows promise as treatment
New strategies for the treatment of obesity and metabolic dysfunctions
Triple-Agonist weist neuen Weg bei Diabetes
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept - ScienceDirect
Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/glucagon triple agonist in the neurodegenerative disease models - Media Centre | EASD
Type 2 Diabetes Mellitus Archives - Immune System Research
Effects, working principles and target tissues of dual agonists... | Download Scientific Diagram
Potent body weight loss, and therapeutic efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP tri-agonist (HM15211) - Media Centre | EASD
IJMS | Free Full-Text | The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome
